The estimated Net Worth of Brian M Stuglik is at least $2.47 Millón dollars as of 17 June 2024. Mr. Stuglik owns over 928 units of Verastem Inc stock worth over $271,726 and over the last 7 years he sold VSTM stock worth over $284,673. In addition, he makes $1,917,190 as Chief Executive Officer y Director at Verastem Inc.
Brian has made over 20 trades of the Verastem Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently he sold 928 units of VSTM stock worth $3,146 on 17 June 2024.
The largest trade he's ever made was selling 28,718 units of Verastem Inc stock on 16 December 2022 worth over $11,487. On average, Brian trades about 4,499 units every 60 days since 2017. As of 17 June 2024 he still owns at least 97,045 units of Verastem Inc stock.
You can see the complete history of Mr. Stuglik stock trades at the bottom of the page.
Brian M. Stuglik is Chief Executive Officer, Director of the company. Mr. Stuglik founded Proventus Health Solutions in January 2016 and has over three decades of experience in U.S. and international pharmaceutical development, product strategy, and commercialization. Prior to founding Proventus Health Solutions, Mr. Stuglik served as the Vice President and Chief Marketing Officer for the oncology division of Eli Lilly and Company, from 2009 to December 2015. Mr. Stuglik received a Bachelor of Science in Pharmacy from Purdue University and holds memberships in the American Society of Clinical Oncology, the American Association of Cancer Research, and the International Association for the Study of Lung Cancer. The Board of Directors believes that Mr. Stuglik’s qualifications to sit on the Board include his extensive experience in pharmaceutical development, product strategy and commercialization.
As the Chief Executive Officer y Director of Verastem Inc, the total compensation of Brian Stuglik at Verastem Inc is $1,917,190. There are no executives at Verastem Inc getting paid more.
Brian Stuglik is 61, he's been the Chief Executive Officer y Director of Verastem Inc since 2019. There are 5 older and 10 younger executives at Verastem Inc. The oldest executive at Verastem Inc is Timothy Barberich, 72, who is the Independent Director.
Brian's mailing address filed with the SEC is C/O PUMA BIOTECHNOLOGY, INC., 10880 WILSHIRE BOULEVARD, SUITE 2150, LOS ANGELES, CA, 90024.
Over the last 13 years, insiders at Verastem Inc have traded over $5,883,823 worth of Verastem Inc stock and bought 3,873,819 units worth $28,318,633 . The most active insiders traders include Capital Management, L.P.Ra ..., Christoph H Westphal y Ansbert Gadicke. On average, Verastem Inc executives and independent directors trade stock every 28 days with the average trade being worth of $112,479. The most recent stock trade was executed by Dan Paterson on 5 August 2024, trading 3,245 units of VSTM stock currently worth $7,009.
verastem, inc. (nasdaq: vstm) is a biopharmaceutical company focused on discovering and developing novel drugs that selectively target cancer stem cells. cancer stem cells are an underlying cause of tumor recurrence and metastasis. verastem is translating breakthrough discoveries in cancer stem cell research into new medicines for the treatment of major cancers such as breast cancer. for more information, please visit www.versatem.com
Verastem Inc executives and other stock owners filed with the SEC include: